A review of human and analogue insulin trials.

A review of human and analogue insulin trials.

A recent meta-analysis evaluated trials of the rapid-acting analogues insulin lispro and insulin aspart, performed before the introduction of the basal analogues, insulin glargine and insulin detemir. This article reviews the effect of rapid-acting and basal insulin analogues separately and in combi...

Descripció completa

Dades bibliogràfiques
Autor principal:	Gough, S
Format:	Journal article
Idioma:	English
Publicat:	2007

Ítems similars

Insulin requirements in patients with diabetes and declining kidney function: differences between insulin analogues and human insulin?
per: Felix Kulozik, et al.
Publicat: (2013-08-01)

Engineering of insulin receptor isoform-selective insulin analogues.
per: Tine Glendorf, et al.
Publicat: (2011-01-01)

Molecular characterisation of long-acting insulin analogues in comparison with human insulin, IGF-1 and insulin X10.
per: Bo F Hansen, et al.
Publicat: (2012-01-01)

Insulin therapy and body weight: benefits of biphasic human insulin analogue NovoMix 30
per: Elena Viktorovna Surkova
Publicat: (2013-03-01)

Safety and Efficacy of Modern Insulin Analogues
per: Hye Jin Yoo, et al.
Publicat: (2013-06-01)

Análogos de insulina Insulin analogues
per: Manuel E. Licea Puig
Publicat: (2006-12-01)

Regular human insulins versus rapid-acting insulin analogues in children and adolescents with type 1 diabetes: a protocol for a systematic review with meta-analysis and Trial Sequential Analysis
per: Johanne Juul Petersen, et al.
Publicat: (2025-01-01)

Insulin degludec is a new ultra-long-acting insulin analogue
per: Ivan Ivanovich Dedov, et al.
Publicat: (2014-07-01)

Insulin analogues and cancer: a note of caution
per: Joseph A.M.J.L. eJanssen, et al.
Publicat: (2014-05-01)

Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
per: Ivan Ivanovich Dedov, et al.
Publicat: (2014-12-01)

Human versus Analogue Insulin for Youth with Type 1 Diabetes in Low-Resource Settings (HumAn-1): protocol for a randomised controlled trial
per: Éimhín Ansbro, et al.
Publicat: (2025-01-01)

Current european regulatory perspectives on insulin analogues
per: Enzmann Harald G, et al.
Publicat: (2011-07-01)

Cross-Reactivity of Insulin Immunoassays Important for Insulin Analogue Detection in Factitious Hypoglycaemia
per: Sachin K. Raj, et al.
Publicat: (2024-06-01)

Modern approach to the evaluation of the pharmacokinetics and pharmacodynamics of biosimilar recombinant human insulin and insulin analogues in I phase clinical study
per: Irina A. Proskurina, et al.
Publicat: (2016-07-01)

Health Technology Assessment on Insulin Analogues: the Rapid Review of Second Type Studies
per: A Oliyaeemanesh, et al.
Publicat: (2012-07-01)

Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis
per: Karla F. S. Melo, et al.
Publicat: (2019-01-01)

Determination of the Biological Activity of Insulin and Its Analogues in Animals
per: P. V. Shadrin, et al.
Publicat: (2023-07-01)

Comparative Study between the Glycemic Control of Human Insulin and Insulin analogue In Sample of Iraqi Type 1 Diabetic Children and Adolescents
per: Noor Wafaa Hashim, et al.
Publicat: (2018-12-01)

COMPARATIVE STUDY OF INTERACTION OF SOME DOMESTIC HUMAN INSULIN SUBSTANCES AND ITS ANALOGUES WITH INSULIN RECEPTOR BY METHOD OF SURFACE PLASMON RESONANCE
per: I. N. Urakova, et al.
Publicat: (2019-01-01)

Subcutaneous fast-acting insulin analogues, alone or in combination with long-acting insulin, versus intravenous regular insulin infusion in patients with diabetic ketoacidosis: protocol for an updated systematic review and meta-analysis of randomised trials
per: Beng Leong Lim, et al.
Publicat: (2023-02-01)

Insulin analogues: new therapies for type 2 diabetes mellitus.
per: Bethel, M, et al.
Publicat: (2002)

Systemically modeling the dynamics of plasma insulin insubcutaneous injection of insulin analogues for type 1 diabetes
per: Jiaxu Li, et al.
Publicat: (2008-11-01)

Modern Approaches to Determination of the Biological Activity of Insulin and Its Analogues
per: T. A. Batuashvili, et al.
Publicat: (2019-06-01)

Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes Mellitus
per: Eun Yeong Choe, et al.
Publicat: (2012-06-01)

Effect of human insulin and insulin analogue on some inflammatory markers and total antioxidant capacity in a sample of Iraqi type 1 diabetic children and adolescents
per: Noor Wafaa Hashim, et al.
Publicat: (2022-04-01)

A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes
per: Chun-Ting Yang, et al.
Publicat: (2021-02-01)

Minimizing Mitogenic Potency of Insulin Analogues Through Modification of a Disulfide Bond
per: Shee Chee Ong, et al.
Publicat: (2022-06-01)

Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients
per: Jakobsen Marie, et al.
Publicat: (2012-09-01)

Prolonged control of insulin-dependent diabetes via intramuscular expression of plasmid-encoded single-strand insulin analogue
per: Lu Deng, et al.
Publicat: (2023-05-01)

Glucagon like peptide 1 analogue, Liraglutide, reduces adipose insulin resistance and hepatic de novo lipogenesis in Nonalcoholic Steatohepatitis: Sub-study results of a phase II randomised-control clinical trial
per: Armstrong, M, et al.
Publicat: (2013)

Biphasic insulin aspart in type 2 diabetes mellitus: an evidence-based medicine review.
per: Gough, S, et al.
Publicat: (2007)

Liraglutide, a human GLP-1 analogue, lowers HbA(1c) independent of weight loss
per: Schmidt, W, et al.
Publicat: (2009)

Insulin degludec: overview of a novel ultra long-acting basal insulin.
per: Gough, S, et al.
Publicat: (2013)

Insulin degludec: Overview of a novel ultra long-acting basal insulin
per: Gough, S, et al.
Publicat: (2013)

Individual stepwise intensification of insulin analogue therapy in type 2 diabetes mellitus
per: Alexander Sergeevich Ametov, et al.
Publicat: (2012-12-01)

Basal insulin analogues in the diabetes mellitus type 2 control — economic aspects
per: D. Yu. Belousov, et al.
Publicat: (2018-06-01)

Study of equivalence and comparable immunogenicity of biosimilar insulin aspart in comparison with the registered analogue
per: Т. L. Karonova, et al.
Publicat: (2022-06-01)

Insulin degludec: a new basal insulin analogue with an ultra-long duration of action. Safety and efficacy in Russian patients with diabetes
per: Marina Vladimirovna Shestakova, et al.
Publicat: (2015-12-01)

Use of human insulin analogues in young patients with type 1 diabetes mellitus: Results of the RESULT observational program on the use of insulin glargine (Lantus) in combination with insulin glulisine (Apidra) as a basal-bolus regimen
per: N V Efremova, et al.
Publicat: (2015-10-01)

Insulin resistance and alterations in the fibrinolytic system
per: Gough, S, et al.
Publicat: (1993)